FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2071-2084 November 16, 2006 Number 20 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Remuzzi, G. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear

ABSTRACT

Background Whether correction of anemia in patients with stage 3 or 4 chronic kidney disease improves cardiovascular outcomes is not established.

Methods We randomly assigned 603 patients with an estimated glomerular filtration rate (GFR) of 15.0 to 35.0 ml per minute per 1.73 m² of body-surface area and mild-to-moderate anemia (hemoglobin level, 11.0 to 12.5 g per deciliter) to a target hemoglobin value in the normal range (13.0 to 15.0 g per deciliter, group 1) or the subnormal range (10.5 to 11.5 g per deciliter, group 2). Subcutaneous erythropoietin (epoetin beta) was initiated at randomization (group 1) or only after the hemoglobin level fell below 10.5 g per deciliter (group 2). The primary end point was a composite of eight cardiovascular events; secondary end points included left ventricular mass index, quality-of-life scores, and the progression of chronic kidney disease.

Results During the 3-year study, complete correction of anemia did not affect the likelihood of a first cardiovascular event (58 events in group 1 vs. 47 events in group 2; hazard ratio, 0.78; 95% confidence interval, 0.53 to 1.14; P=0.20). Left ventricular mass index remained stable in both groups. The mean estimated GFR was 24.9 ml per minute in group 1 and 24.2 ml per minute in group 2 at baseline and decreased by 3.6 and 3.1 ml per minute per year, respectively (P=0.40). Dialysis was required in more patients in group 1 than in group 2 (127 vs. 111, P=0.03). General health and physical function improved significantly (P=0.003 and P<0.001, respectively, in group 1, as compared with group 2). There was no significant difference in the combined incidence of adverse events between the two groups, but hypertensive episodes and headaches were more prevalent in group 1.

Conclusions In patients with chronic kidney disease, early complete correction of anemia does not reduce the risk of cardiovascular events. (ClinicalTrials.gov number, NCT00321919 [ClinicalTrials.gov] .)

Source Information

From Inserm Unité 507 and Assistance Publique–Hôpitaux de Paris, Necker Hospital, Division of Nephrology, Paris (T.B.D.); the Department of Nephrology and Dialysis, Ospedale A. Manzoni, Lecco, Italy (F.L.); the Department of Nephrology, University Hospital Lund, Lund, Sweden (N.C.); the Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany, and the First Medical Clinic, Mannheim University Hospital, University of Heidelberg, Heidelberg, Germany (K.-U.E.); the Department of Renal Medicine, King's College Hospital, London (I.C.M.); the Department of Nephrology, General Hospital of Veria, Veria, Greece (D.T.); and the Pharmaceutical Division, F. Hoffmann–La Roche, Basel, Switzerland (H.-U.B., A.S.).

Address reprint requests to Dr. Drüeke at Unité 507 de l'INSERM and Service de Néphrologie, Hôpital Necker, Université Paris-V, Paris, France, or at drueke{at}necker.fr.

Full Text of this Article

This article has been cited by other articles:

• Marsden, P. A. (2009). Treatment of Anemia in Chronic Kidney Disease -- Strategies Based on Evidence. NEJM 361: 2089-2090 [Full Text]  
• Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., Lewis, E. F., McGill, J. B., McMurray, J. J.V., Parfrey, P., Parving, H.-H., Remuzzi, G., Singh, A. K., Solomon, S. D., Toto, R., the TREAT Investigators, (2009). A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. NEJM 361: 2019-2032 [Abstract] [Full Text]  
• Macdougall, I. C., Rossert, J., Casadevall, N., Stead, R. B., Duliege, A.-M., Froissart, M., Eckardt, K.-U. (2009). A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia. NEJM 361: 1848-1855 [Abstract] [Full Text]  
• Newsome, B. B., Onufrak, S. J., Warnock, D. G., McClellan, W. M. (2009). Exploration of anaemia as a progression factor in African Americans with cardiovascular disease. Nephrol Dial Transplant 24: 3404-3411 [Abstract] [Full Text]  
• Conway, B. N., Miller, R. G., Klein, R., Orchard, T. J. (2009). Prediction of Proliferative Diabetic Retinopathy With Hemoglobin Level. Arch Ophthalmol 127: 1494-1499 [Abstract] [Full Text]  
• Klapholz, M., Abraham, W. T., Ghali, J. K., Ponikowski, P., Anker, S. D., Knusel, B., Sun, Y., Wasserman, S. M., van Veldhuisen, D. J. (2009). The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure. Eur J Heart Fail 11: 1071-1077 [Abstract] [Full Text]  
• Bacchus, S., O'Mara, N., Manley, H., Fishbane, S. (2009). Meeting New Challenges in the Management of Anemia of Chronic Kidney Disease Through Collaborative Care with Pharmacists. The Annals of Pharmacotherapy 43: 1857-1866 [Abstract] [Full Text]  
• Treleaven, D. J, Clase, C. M (2009). Use of erythropoietins in patients with renal transplants. BMJ 339: b3825-b3825 [Full Text]  
• Heinze, G., Kainz, A., Horl, W. H, Oberbauer, R. (2009). Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study. BMJ 339: b4018-b4018 [Abstract] [Full Text]  
• Wetmore, J. B., Rigler, S. K., Mahnken, J. D., Mukhopadhyay, P., Shireman, T. I. (2009). Considering health insurance: how do dialysis initiates with Medicaid coverage differ from persons without Medicaid coverage?. Nephrol Dial Transplant 0: gfp396v1-gfp396 [Abstract] [Full Text]  
• Aapro, M. (2009). An Update on Twenty Years of Anemia Management with Erythropoiesis-Stimulating Agents in Nephrology and Oncology/Hematology. The Oncologist 14: 1-5 [Full Text]  
• Locatelli, F., Becker, H. (2009). Update on Anemia Management in Nephrology, Including Current Guidelines on the Use of Erythropoiesis-Stimulating Agents and Implications of the Introduction of "Biosimilars". The Oncologist 14: 16-21 [Abstract] [Full Text]  
• Besarab, A., Horl, W. H., Silverberg, D. (2009). Iron Metabolism, Iron Deficiency, Thrombocytosis, and the Cardiorenal Anemia Syndrome. The Oncologist 14: 22-33 [Abstract] [Full Text]  
• Spivak, J. L., Gascon, P., Ludwig, H. (2009). Anemia Management in Oncology and Hematology. The Oncologist 14: 43-56 [Abstract] [Full Text]  
• Locatelli, F., Gascon, P. (2009). Is Nephrology More at Ease Than Oncology with Erythropoiesis-Stimulating Agents? Treatment Guidelines and an Update on Benefits and Risks. The Oncologist 14: 57-62 [Abstract] [Full Text]  
• van der Meer, P, Groenveld, H F, Januzzi, J L Jr, van Veldhuisen, D J (2009). Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart 95: 1309-1314 [Abstract] [Full Text]  
• Smith, K., Semple, D., Bhandari, S., Seymour, A.-M. L. (2009). Cellular basis of uraemic cardiomyopathy: a role for erythropoietin?. Eur J Heart Fail 11: 732-738 [Abstract] [Full Text]  
• McMurray, J. J.V., Anand, I. S., Diaz, R., Maggioni, A. P., O'Connor, C., Pfeffer, M. A., Polu, K. R., Solomon, S. D., Sun, Y., Swedberg, K., Tendera, M., van Veldhuisen, D. J., Wasserman, S. M., Young, J. B., on behalf of the RED-HF Committees and Investigato, (2009). Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 11: 795-801 [Abstract] [Full Text]  
• Mehdi, U., Toto, R. D. (2009). Anemia, Diabetes, and Chronic Kidney Disease. Diabetes Care 32: 1320-1326 [Full Text]  
• Ishani, A., Guo, H., Arneson, T. J., Gilbertson, D. T., Mau, L.-W., Li, S., Dunning, S., Collins, A. J. (2009). Possible Effects of the New Medicare Reimbursement Policy on African Americans with ESRD. J. Am. Soc. Nephrol. 20: 1607-1613 [Full Text]  
• Singh, A. K., Himmelfarb, J., Szczech, L. A. (2009). Resolved: Targeting a Higher Hemoglobin Is Associated with Greater Risk in Patients with CKD Anemia: Pro. J. Am. Soc. Nephrol. 20: 1436-1443 [Abstract] [Full Text]  
• Moossavi, S., Freedman, B. I. (2009). Treating Anemia With Erythropoiesis-Stimulating Agents: Effects on Quality of Life. Arch Intern Med 169: 1100-1101 [Full Text]  
• Clement, F. M., Klarenbach, S., Tonelli, M., Johnson, J. A., Manns, B. J. (2009). The Impact of Selecting a High Hemoglobin Target Level on Health-Related Quality of Life for Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis. Arch Intern Med 169: 1104-1112 [Abstract] [Full Text]  
• Hage, F. G., Venkataraman, R., Zoghbi, G. J., Perry, G. J., DeMattos, A. M., Iskandrian, A. E. (2009). The scope of coronary heart disease in patients with chronic kidney disease.. J Am Coll Cardiol 53: 2129-2140 [Abstract] [Full Text]  
• Ferrari, P., Xiao, J., Ukich, A., Irish, A. (2009). Estimation of glomerular filtration rate: does haemoglobin discriminate between ageing and true CKD?. Nephrol Dial Transplant 24: 1828-1833 [Abstract] [Full Text]  
• Chan, K., Moran, J., Hlatky, M., Lafayette, R. (2009). Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients. Nephrol Dial Transplant 24: 1956-1962 [Abstract] [Full Text]  
• Anker, S. D., Voors, A., Okonko, D., Clark, A. L., James, M. K., von Haehling, S., Kjekshus, J., Ponikowski, P., Dickstein, K., for the OPTIMAAL Investigators, (2009). Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. Eur Heart J 30: 1331-1339 [Abstract] [Full Text]  
• Vanholder, R., Abramowicz, D., Cannata-Andia, J. B., Cocchi, V., Cochat, P., Covic, A., Eckardt, K.-U., Fouque, D., Heimburger, O., Jenkins, S., MacLeod, A., Lindley, E., Locatelli, F., London, G., Marti i Monros, A., Spasovski, G., Tattersall, J., Van Biesen, W., Wanner, C., Wiecek, A., Zoccali, C. (2009). The future of European Nephrology 'Guidelines'--a declaration of intent by European Renal Best Practice (ERBP). NDT Plus 2: 213-221 [Full Text]  
• Anderson, S., Halter, J. B., Hazzard, W. R., Himmelfarb, J., Horne, F. M., Kaysen, G. A., Kusek, J. W., Nayfield, S. G., Schmader, K., Tian, Y., Ashworth, J. R., Clayton, C. P., Parker, R. P., Tarver, E. D., Woolard, N. F., High, K. P., for the workshop participants, (2009). Prediction, Progression, and Outcomes of Chronic Kidney Disease in Older Adults. J. Am. Soc. Nephrol. 20: 1199-1209 [Abstract] [Full Text]  
• Ensor, C. R, Kockler, D. R, Dugger, R. W, Hylton-Gravatt, L. A. (2009). Erythropoiesis-Stimulating Agents: Creation and Validation of a Computerized Prescriber Order Entry Alert. The Annals of Pharmacotherapy 43: 1143-1144 [Full Text]  
• Tonelli, M., Hemmelgarn, B., Reiman, T., Manns, B., Reaume, M. N., Lloyd, A., Wiebe, N., Klarenbach, S. (2009). Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 180: E62-E71 [Abstract] [Full Text]  
• Arneson, T. J., Zaun, D., Peng, Y., Solid, C. A., Dunning, S., Gilbertson, D. T. (2009). Comparison of methodologies to characterize haemoglobin variability in the US Medicare haemodialysis population. Nephrol Dial Transplant 24: 1378-1383 [Full Text]  
• Spiegel, D. M., Chertow, G. M. (2009). Lost Without Directions: Lessons from the Anemia Debate and the Drive Study. CJASN 4: 1009-1010 [Abstract] [Full Text]  
• Vaziri, N. D., Zhou, X. J. (2009). Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant 24: 1082-1088 [Full Text]  
• Parfrey, P. S., Lauve, M., Latremouille-Viau, D., Lefebvre, P. (2009). Erythropoietin Therapy and Left Ventricular Mass Index in CKD and ESRD Patients: A Meta-Analysis. CJASN 4: 755-762 [Abstract] [Full Text]  
• Foley, R. N., Curtis, B. M., Parfrey, P. S. (2009). Erythropoietin Therapy, Hemoglobin Targets, and Quality of Life in Healthy Hemodialysis Patients: A Randomized Trial. CJASN 4: 726-733 [Abstract] [Full Text]  
• Krikorian, S. A. (2009). Managing Anemia of Chronic Kidney Disease. AMERICAN JOURNAL OF LIFESTYLE MEDICINE 3: 135-146 [Abstract]  
• Ibrahim, H. N., Foley, R. N., Zhang, R., Gilbertson, D. T., Collins, A. J. (2009). Parenteral Iron Use: Possible Contribution to Exceeding Target Hemoglobin in Hemodialysis Patients. CJASN 4: 623-629 [Abstract] [Full Text]  
• Kalantar-Zadeh, K., Aronoff, G. R. (2009). Hemoglobin Variability in Anemia of Chronic Kidney Disease. J. Am. Soc. Nephrol. 20: 479-487 [Abstract] [Full Text]  
• Kazory, A., Ross, E. A. (2009). Anemia: the point of convergence or divergence for kidney disease and heart failure?. J Am Coll Cardiol 53: 639-647 [Abstract] [Full Text]  
• Pagourelias, E. D., Koumaras, C., Kakafika, A. I., Tziomalos, K., Zorou, P. G., Athyros, V. G., Karagiannis, A. (2009). Cardiorenal Anemia Syndrome: Do Erythropoietin and Iron Therapy Have a Place in the Treatment of Heart Failure?. ANGIOLOGY 60: 74-81 [Abstract]  
• Provenzano, R., Schiller, B., Rao, M., Coyne, D., Brenner, L., Pereira, B. J.G. (2009). Ferumoxytol as an Intravenous Iron Replacement Therapy in Hemodialysis Patients. CJASN 4: 386-393 [Abstract] [Full Text]  
• Krapf, R., Hulter, H. N. (2009). Arterial Hypertension Induced by Erythropoietin and Erythropoiesis-Stimulating Agents (ESA). CJASN 4: 470-480 [Abstract] [Full Text]  
• Paige, N. M., Nagami, G. T. (2009). The Top 10 Things Nephrologists Wish Every Primary Care Physician Knew. Mayo Clin Proc. 84: 180-186 [Abstract] [Full Text]  
• Heung, M., Mueller, B. A, Segal, J. H (2009). Optimizing Anemia Management in Hospitalized Patients with End-Stage Renal Disease. The Annals of Pharmacotherapy 43: 276-282 [Abstract] [Full Text]  
• Finkelstein, F. O., Story, K., Firanek, C., Mendelssohn, D., Barre, P., Takano, T., Soroka, S., Mujais, S. (2009). Health-Related Quality of Life and Hemoglobin Levels in Chronic Kidney Disease Patients. CJASN 4: 33-38 [Abstract] [Full Text]  
• Staples, A. O., Wong, C. S., Smith, J. M., Gipson, D. S., Filler, G., Warady, B. A., Martz, K., Greenbaum, L. A. (2009). Anemia and Risk of Hospitalization in Pediatric Chronic Kidney Disease. CJASN 4: 48-56 [Abstract] [Full Text]  
• de Francisco, A. L. M. (2009). Key insights into present and future treatments of anaemia in CKD patients. NDT Plus 2: i1-i2 [Full Text]  
• Anker, S. D., Toto, R. (2009). Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients. NDT Plus 2: i3-i8 [Abstract] [Full Text]  
• de Francisco, A. L. M., Stenvinkel, P., Vaulont, S. (2009). Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness. NDT Plus 2: i18-i26 [Abstract] [Full Text]  
• Metzger, N. L., Francis, K. E., Voils, S. A. (2008). A Comparative Review of Erythropoiesis Stimulating Agents. Journal of Pharmacy Practice 21: 424-430 [Abstract]  
• Saltiel, M. (2008). The Erythropoietic Receptors Agonists: FDA Warnings, Changing Guidelines, and Other Responses to Negative Data. Journal of Pharmacy Practice 21: 402-404 [Abstract]  
• Silverberg, D. S., Wexler, D., Iaina, A., Schwartz, D. (2008). The Role of Correction of Anemia in Patients With Congestive Heart Failure Associated with Chronic Kidney Failure. Journal of Pharmacy Practice 21: 420-423 [Abstract]  
• Radbill, B., Murphy, B., LeRoith, D. (2008). Rationale and Strategies for Early Detection and Management of Diabetic Kidney Disease. Mayo Clin Proc. 83: 1373-1381 [Abstract] [Full Text]  
• Levin, A. MD, Hemmelgarn, B. MD PhD, Culleton, B. MD MSc, Tobe, S. MD, McFarlane, P. MD PhD, Ruzicka, M. MD PhD, Burns, K. MD, Manns, B. MD MSc, White, C. MD, Madore, F. MD MSc, Moist, L. MD MSc, Klarenbach, S. MD MSc, Barrett, B. MD MSc, Foley, R. MD MSc, Jindal, K. MD, Senior, P. MBBS PhD, Pannu, N. MD MSc, Shurraw, S. MD, Akbari, A. MD, Cohn, A. MD, Reslerova, M. MD PhD, Deved, V. MD, Mendelssohn, D. MD, Nesrallah, G. MD, Kappel, J. MD, Tonelli, M. MD SM, for the Canadian Society of Nephrology, (2008). Guidelines for the management of chronic kidney disease. CMAJ 179: 1154-1162 [Full Text]  
• Canaud, B., Mingardi, G., Braun, J., Aljama, P., Kerr, P. G., Locatelli, F., Villa, G., Van Vlem, B., McMahon, A. W., Kerloeguen, C., Beyer, U., on behalf of the STRIATA Study Investigators, (2008). Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 23: 3654-3661 [Abstract] [Full Text]  
• Foley, R. N., Curtis, B. M., Parfrey, P. S. (2008). Hemoglobin Targets and Blood Transfusions in Hemodialysis Patients without Symptomatic Cardiac Disease Receiving Erythropoietin Therapy. CJASN 3: 1669-1675 [Abstract] [Full Text]  
• Summers, S., Holdsworth, S., Sharples, E. (2008). The (re)challenging question of erythropoiesis-stimulating agents inducing pure red cell aplasia. Nephrol Dial Transplant 23: 3053-3055 [Full Text]  
• Sijpkens, Y. W. J., Berkhout-Byrne, N. C., Rabelink, T. J. (2008). Optimal predialysis care. NDT Plus 1: iv7-iv13 [Abstract] [Full Text]  
• Groenveld, H. F., Januzzi, J. L., Damman, K., van Wijngaarden, J., Hillege, H. L., van Veldhuisen, D. J., van der Meer, P. (2008). Anemia and Mortality in Heart Failure Patients: A Systematic Review and Meta-Analysis. J Am Coll Cardiol 52: 818-827 [Abstract] [Full Text]  
• Chonchol, M., Lippi, G., Montagnana, M., Muggeo, M., Targher, G. (2008). Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis. Nephrol Dial Transplant 23: 2879-2883 [Abstract] [Full Text]  
• Chan, K. E., Lafayette, R. A., Whittemore, A. S., Hlatky, M. A., Moran, J. (2008). Facility factors dominate the ability to achieve target haemoglobin levels in haemodialysis patients. Nephrol Dial Transplant 23: 2948-2956 [Abstract] [Full Text]  
• Singh, A. K., Kelley, K., Agarwal, R. (2008). Interpreting Results of Clinical Trials: A Conceptual Framework. CJASN 3: 1246-1252 [Full Text]  
• Sihler, K. C., Napolitano, L. M. (2008). Anemia of Inflammation in Critically Ill Patients. J Intensive Care Med 23: 295-302 [Abstract]  
• Silverberg, D. S., Wexlerb, D., Iaina, A., Schwartz, D. (2008). The role of correction of anaemia in patients with congestive heart failure: A short review. Eur J Heart Fail 10: 819-823 [Abstract] [Full Text]  
• Anand, I. S. (2008). Anemia and Chronic Heart Failure: Implications and Treatment Options. J Am Coll Cardiol 52: 501-511 [Abstract] [Full Text]  
• Zarychanski, R. MD, Houston, D. S. MD PhD (2008). Anemia of chronic disease: A harmful disorder or an adaptive, beneficial response?. CMAJ 179: 333-337 [Full Text]  
• Schlieper, G., Hristov, M., Brandenburg, V., Kruger, T., Westenfeld, R., Mahnken, A. H., Yagmur, E., Boecker, G., Heussen, N., Gladziwa, U., Ketteler, M., Weber, C., Floege, J. (2008). Predictors of low circulating endothelial progenitor cell numbers in haemodialysis patients. Nephrol Dial Transplant 23: 2611-2618 [Abstract] [Full Text]  
• Swinkels, D. W., Wetzels, J. F. M. (2008). Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease?. Nephrol Dial Transplant 23: 2450-2453 [Full Text]  
• Spinowitz, B. S., Kausz, A. T., Baptista, J., Noble, S. D., Sothinathan, R., Bernardo, M. V., Brenner, L., Pereira, B. J. G. (2008). Ferumoxytol for Treating Iron Deficiency Anemia in CKD. J. Am. Soc. Nephrol. 19: 1599-1605 [Abstract] [Full Text]  
• Maekawa, K., Shoji, T., Emoto, M., Okuno, S., Yamakawa, T., Ishimura, E., Inaba, M., Nishizawa, Y. (2008). Influence of atherosclerosis on the relationship between anaemia and mortality risk in haemodialysis patients. Nephrol Dial Transplant 23: 2329-2336 [Abstract] [Full Text]  
• Chhabra, D., Grafals, M., Skaro, A. I., Parker, M., Gallon, L. (2008). Impact of Anemia after Renal Transplantation on Patient and Graft Survival and on Rate of Acute Rejection. CJASN 3: 1168-1174 [Abstract] [Full Text]  
• DEMIRJIAN, S. G., NURKO, S. (2008). Anemia of chronic kidney disease: When normalcy becomes undesirable. Cleveland Clinic Journal of Medicine 75: 353-356 [Abstract] [Full Text]  
• Ishani, A., Solid, C. A., Weinhandl, E. D., Gilbertson, D. T., Foley, R. N., Collins, A. J. (2008). Association between number of months below K/DOQI haemoglobin target and risk of hospitalization and death. Nephrol Dial Transplant 23: 1682-1689 [Abstract] [Full Text]  
• Kitamura, H., Isaka, Y., Takabatake, Y., Imamura, R., Suzuki, C., Takahara, S., Imai, E. (2008). Nonerythropoietic derivative of erythropoietin protects against tubulointerstitial injury in a unilateral ureteral obstruction model. Nephrol Dial Transplant 23: 1521-1528 [Abstract] [Full Text]  
• Minamishima, Y. A., Moslehi, J., Bardeesy, N., Cullen, D., Bronson, R. T., Kaelin, W. G. Jr (2008). Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood 111: 3236-3244 [Abstract] [Full Text]  
• Furumatsu, Y., Nagasawa, Y., Hamano, T., Iwatani, H., Iio, K., Shoji, T., Ito, T., Tsubakihara, Y., Imai, E. (2008). Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan. Nephrol Dial Transplant 23: 984-990 [Abstract] [Full Text]  
• Coviello, A. D., Kaplan, B., Lakshman, K. M., Chen, T., Singh, A. B., Bhasin, S. (2008). Effects of Graded Doses of Testosterone on Erythropoiesis in Healthy Young and Older Men. J. Clin. Endocrinol. Metab. 93: 914-919 [Abstract] [Full Text]